Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi

Biogen (BIIB) secured FDA approval for Leqembi Iqlik, enabling early Alzheimer’s patients to begin treatment using a weekly at-home autoinjector rather than biweekly IV infusions. The shift to less frequent, more convenient dosing is a meaningful commercialization and adoption tailwind for the therapy.

Analysis

Biogen (BIIB) secured FDA approval for Leqembi Iqlik, enabling early Alzheimer’s patients to begin treatment using a weekly at-home autoinjector rather than biweekly IV infusions. The shift to less frequent, more convenient dosing is a meaningful commercialization and adoption tailwind for the therapy.